 Bevacizumab is a humanized monoclonal antibody which binds to VEGF Vascular Endothelial Growth Factor. In association with double-drug standard chemotherapies, it has been proven that bevacizumab can improve survival of previously untreated advanced non-small-cell lung cancers NSCLC, compared to chemotherapy without bevacizumab. Such promising effects on NSCLC deserve to be tested on small-cell lung cancers. 